10X Genomics - The Story Behind the Single-Cell Revolution - $TXG

10X Genomics sprung from a simple but disruptive idea—stop averaging millions of cells and start listening to each one—and turned that insight into a platform (Chromium + Visium + Xenium) that rewired modern biology: fast microfluidics, barcode-laden gel beads, and user-friendly software made single-cell and spatial analysis scalable, drove thousands of high-impact papers, and powered a blockbuster IPO, even as bitter patent battles and the arrival of cheaper competitors forced the company into a fight for its future. Along the way 10X expanded beyond dissociated cells into spatial and in situ modalities, aimed at clinical-grade workflows, and doubled down on scale with GEM-X and partnerships like the Billion Cells Project to feed next-generation AI—yet the post-boom biotech winter, rising rivals such as Parse, and the pressure to lower per-cell costs have created a strategic crossroads: defend premium quality and clinical upside, or lean into commoditization to keep labs buying in. It’s a story of brilliant technical execution, platform economics, and hard-earned brand equity now being tested by market realities---Subscribe to our newsletter on LinkedIn https://www.linkedin.com/build-relation/newsletter-follow?entityUrn=7408775804387491842Follow us on X @emportop---Transcript https://empor.top/us/TXGI. Introduction & Episode RoadmapII. The Genomics Revolution & Founding ContextIII. The Fluidigm Years & Birth of GemCodeIV. Building the Platform: Chromium Launch (2015)V. The Single-Cell Biology Explosion (2016-2018)VI. Going Spatial: Visium & The Next Frontier (2018-2020)VII. IPO & Public Company Journey (2019-2021)VIII. The Great Reset & Strategic Inflection (2021-2023)IX. The Clinical & AI Pivot (2023-Present)X. The Business Model Deep-DiveXI. Porter's Five Forces AnalysisXII. Hamilton's Seven Powers AnalysisXIII. Strategic Crossroads & The Path ForwardXIV. Playbook: Lessons for Founders & InvestorsXV. Epilogue & Current StateXVI. Key Takeaways & ReflectionXVII. Outro & Further Resources